Published in PLoS One on October 24, 2014
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00747734
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity. Cell (2017) 2.06
Characterization of Diabetogenic CD8+ T Cells: IMMUNE THERAPY WITH METABOLIC BLOCKADE. J Biol Chem (2016) 0.76
A Role for Regulatory T Cells in a Murine Model of Epicutaneous Toluene Diisocyanate Sensitization. Toxicol Sci (2016) 0.76
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet (2001) 14.15
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 10.32
Molecular and functional profiling of memory CD8 T cell differentiation. Cell (2002) 8.06
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell (2003) 4.42
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
A requirement for neuropilin-1 in embryonic vessel formation. Development (1999) 3.95
A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity (1999) 3.84
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature (2011) 3.25
Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med (2012) 2.97
Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity (2008) 2.97
Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol (2004) 2.82
Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity (2000) 2.71
A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol (2002) 2.47
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature (2013) 1.99
Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res (2006) 1.93
Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development (1995) 1.85
Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem (2002) 1.81
Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. J Leukoc Biol (2008) 1.72
The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem (2000) 1.60
Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system. J Neurobiol (1996) 1.60
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med (2012) 1.38
Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology (2007) 1.22
Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J Immunol (2001) 1.15
Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother (2013) 1.05
Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother (2009) 1.02
Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2011) 1.02
Growth-associated expression of a membrane protein, neuropilin, in Xenopus optic nerve fibers. Dev Neurosci (1995) 1.01
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res (2012) 0.98
The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer (2013) 0.98
The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol (2010) 0.97
Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res (2012) 0.94
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.92
Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep (2013) 0.90
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs (2014) 0.84
Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance. J Leukoc Biol (2014) 0.82
Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy (2014) 0.81